Identification

Name
Famotidine
Accession Number
DB00927
Description

Famotidine is a competitive histamine-2 (H2) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children.8 Compared to other H2 receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis.2 Famotidine is used in various over-the-counter and off-label uses.8 While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.6

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 337.445
Monoisotopic: 337.044934829
Chemical Formula
C8H15N7O2S3
Synonyms
  • (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
  • 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
  • 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
  • Famotidina
  • Famotidine
  • Famotidinum
  • N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
External IDs
  • L 643341
  • MK-208
  • YM-11170

Pharmacology

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.5

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.5

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.6

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.8,9

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Famotidine decreases the production of gastric acid, suppresses acid concentration and pepsin content, and decreases the volume of gastric secretion. Famotidine inhibits both basal and nocturnal gastric acid secretion, as well as acid secretion stimulated by food, caffeine, insulin, and pentagastrin.5,6

Famotidine has a dose-dependent therapeutic action, with the highest dose having the most extended duration of action and the highest inhibitory effect on gastric acid secretion. Following oral administration, the onset of action is within one hour, and the peak effect is reached within 1-3 hours. The duration of effect is about 10-12 hours.1

Mechanism of action

Histamine acts as a local hormone that stimulates the acid output by parietal cells via a paracrine mechanism. Neuroendocrine cells called enterochromaffin-like (ECL) cells lie close to the parietal cells and regulate the basal secretion of histamine. Histamine release is also promoted from stimulation by acetylcholine and gastrin, a peptide hormone. Gastrin (G) cells release gastrin, which works on CCK2 receptors on ECL cells. This action promotes the release of histamine from ECL cells. Upon release, histamine acts on H2 receptors expressed on the basolateral membrane of parietal cells, leading to increased intracellular cAMP levels and activated proton pumps on parietal cells. Proton pump releases more protons into the stomach, thereby increasing the secretion of acid. 4 In conditions that are associated with acid hypersecretion such as ulcers, there is a loss of regulation of acid secretion. Famotidine works on H2 receptors and blocks the actions of histamine.8

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Humans
Absorption

Following oral administration, the absorption of famotidine is dose-dependent and incomplete.3 The oral bioavailability ranges from 40-50%, and the Cmax is reached in 1-4 hours post-dosing.1,3 While the bioavailability can be slightly increased with the intake of food and decreased by antacids, there is no clinical significance.5

Volume of distribution

The steady-state volume of distribution ranges from 1.0 to 1.3 L/kg.3 Famotidine is found in breast milk; however, it is found in breast milk at the lowest concentrations compared to other H2 receptor antagonists.8

Protein binding

The protein binding of famotidine is about 15 to 22%.3

Metabolism

Famotidine undergoes minimal first-pass metabolism. About 25-30% of the drug is eliminated through hepatic metabolism. The only metabolite identified in humans is the S-oxide.5

Hover over products below to view reaction partners

Route of elimination

About 65-70% of the total administered dose of famotidine undergoes renal elimination, and 30-35% of the dose is cleared by metabolism.5 Following intravenous administration, about 70% of the drug is eliminated in the urine as an unchanged drug.3

Half-life

The elimination half-life is about 2 to 4 hours.3 The half-life is expected to increase nonlinearly in patients with decreased renal function.1

Clearance

Renal clearance is 250-450 mL/min, indicating some tubular excretion. Because the renal clearance rate exceeds the glomerular filtration rate, famotidine is thought to be mainly eliminated via both glomerular filtration and renal tubular secretion.3

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The oral LD50 is 4049 mg/kg in rats and 4686 mg/kg in mice. The subcutaneous LD50 is 800 mg/kg in rats and mice. The lowest published toxic dose (TDLo) in man following oral administration is 4 mg/kg/7D.7

Symptoms of overdose resemble the adverse events seen with the use of recommended doses, and they should be responded with supportive and symptomatic treatment. Any unabsorbed drug should be removed from the gastrointestinal tract, and the patient should be monitored accordingly. The use of hemodialysis to eliminate the drug from the systemic circulation is effective, but the experience of using hemodialysis in response to famotidine overdose is limited in clinical settings.5

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Famotidine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Famotidine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Famotidine.
Acetylsalicylic acidThe excretion of Famotidine can be decreased when combined with Acetylsalicylic acid.
AcrivastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Acrivastine.
AcyclovirThe excretion of Famotidine can be decreased when combined with Acyclovir.
AdenosineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Adenosine.
AgomelatineThe metabolism of Agomelatine can be decreased when combined with Famotidine.
AjmalineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ajmaline.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Famotidine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid excessive or chronic alcohol consumption. Alcohol increases the risk of gastric irritation.
  • Limit caffeine intake. Caffeine and other acidic beverages increases the risk of gastric irritation.
  • Take with or without food. Food slightly increases bioavailability, but not to a clinically significant extent.

Products

Product Images
International/Other Brands
Amfamox / Antodine / Confobos / Cronol / Digervin / Dispromil / Duovel / Durater / Famocid / Famosan / Famotep / Famox / Famoxal / Famtac / Famulcer / Fanosin / Gaster / Lecedil / Motiax / Mylanta AR / Notidin / Nulceran / Panalba / Pepcid RPD / Pepcidin / Pepcidine / Pepdine / Pepfamin / Quamatel / Renapepsa / Rubacina / Sedanium-R / Supertidine / Tairal / Tipodex / Ulfagel / Ulfamid / Ulgarine / Vagostal
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bci FamotidineTabletOralBaker Cummins IncNot applicableNot applicableCanada
Bci FamotidineTabletOralBaker Cummins IncNot applicableNot applicableCanada
FamotidinePowder, for suspension40 mg/5mLOralPaddock Laboratories, Inc.2010-05-282015-04-30Us
FamotidineInjection, solution2 mg/1mLIntravenousCantrell Drug Company2014-06-11Not applicableUs
Famotidine InjectionSolutionIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Famotidine InjectionSolutionIntravenousHospira Healthcare UlcNot applicableNot applicableCanada
Famotidine InjectionSolutionIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Famotidine InjectionSolutionIntravenousFresenius KabiNot applicableNot applicableCanada
Famotidine IV InjectionSolutionIntravenousTEVA Canada LimitedNot applicableNot applicableCanada
Famotidine IV InjectionSolutionIntravenousTEVA Canada LimitedNot applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-famotidine InjectableSolutionIntravenousApotex Corporation2003-11-172013-08-02Canada
Apo-famotidine InjectableSolutionIntravenousApotex Corporation2004-05-272013-08-02Canada
Apo-famotidine Tab 20mg USPTabletOralApotex Corporation1993-12-31Not applicableCanada
Apo-famotidine Tab 40mg USPTabletOralApotex Corporation1993-12-31Not applicableCanada
FamotidineTablet20 mg/1OralProficient Rx LP2001-04-16Not applicableUs
FamotidineTablet, coated20 mg/1OralTeva2008-04-302008-04-30Us
FamotidineTablet20 mg/1OralCardinal Health2001-04-16Not applicableUs
FamotidineTablet, film coated20 mg/1OralWockhardt2001-04-16Not applicableUs
FamotidineInjection10 mg/1mLIntravenousWest-Ward Pharmaceuticals Corp.2001-04-16Not applicableUs
FamotidineTablet, film coated20 mg/1OralA-S Medication Solutions2001-04-16Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
7 Select Acid ControllerTablet20 mg/1Oral7-Eleven2014-08-052020-01-31Us
Acid ControlTabletOralVita Health Products Inc1998-10-27Not applicableCanada
Acid ControlTabletOralApotex Corporation2000-07-11Not applicableCanada
Acid ControlTabletOralTEVA Canada Limited1997-06-172019-07-09Canada
Acid ControlTabletOralPendopharm Division Of Pharmascience Inc1997-09-082015-01-19Canada
Acid ControlTabletOralApotex Corporation2014-04-28Not applicableCanada
Acid Control Original StrengthTablet10 mg/1OralMedicine Shoppe International2009-10-192012-04-09Us
Acid ControllerTablet, film coated20 mg/1OralWalgreen Company2006-09-26Not applicableUs
Acid ControllerTablet, film coated10 mg/1OralH E B2015-10-23Not applicableUs
Acid ControllerTablet, film coated20 mg/1OralH E B2016-09-14Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Acid Controller CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-01-15Us
Acid Controller CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralSafeway2008-08-062017-01-19Us
Acid Controller CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052016-11-16Us
Acid Controller Complete dual actionFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-302017-07-25Us
Acid Controller Complete dual actionFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen Company2008-07-30Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen Company2016-01-29Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating Co., LLC2016-01-12Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralRite Aid2009-05-152017-09-08Us
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen Company2016-01-29Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating Co., LLC2016-01-06Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FamotidineFamotidine (2 mg/1mL)Injection, solutionIntravenousCantrell Drug Company2014-06-11Not applicableUs

Categories

ATC Codes
A02BA03 — FamotidineA02BA53 — Famotidine, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Thiazoles
Direct Parent
2,4-disubstituted thiazoles
Alternative Parents
Organic sulfuric acids and derivatives / Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
2,4-disubstituted 1,3-thiazole / Amidine / Aromatic heteromonocyclic compound / Azacycle / Dialkylthioether / Guanidine / Heteroaromatic compound / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound
show 9 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, guanidines, 1,3-thiazole (CHEBI:4975)

Chemical Identifiers

UNII
5QZO15J2Z8
CAS number
76824-35-6
InChI Key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
IUPAC Name
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
SMILES
NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1

References

Synthesis Reference

Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.

US5021582
General References
  1. Chremos AN: Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003. [PubMed:2887616]
  2. Langtry HD, Grant SM, Goa KL: Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005. [PubMed:2573505]
  3. Echizen H, Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. [PubMed:1764869]
  4. 29. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 360-363). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  5. FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
  6. Mylan Pharmaceuticals Product Monograph: Famotidine, for intravenous injection [Link]
  7. Cayman Chemical: Famotidine MSDS [Link]
  8. Famotidine - StatPearls - NCBI Bookshelf [Link]
  9. Prophylaxis and management of stress ulceration - NCBI [Link]
Human Metabolome Database
HMDB0001919
KEGG Drug
D00318
PubChem Compound
3325
PubChem Substance
46507397
ChemSpider
3208
BindingDB
50036754
RxNav
4278
ChEBI
4975
ChEMBL
CHEMBL902
ZINC
ZINC000001530636
Therapeutic Targets Database
DAP000341
PharmGKB
PA449586
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Famotidine
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (1.05 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
4CompletedDiagnosticAcute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI)1
4CompletedPreventionAcute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI)1
4CompletedPreventionMarginal Ulcers1
4CompletedPreventionPeptic Ulcer1
4CompletedPreventionPeptic Ulcer/Erosions1
4CompletedPreventionPulmonary Aspiration of Gastric Contents1
4CompletedPreventionUlcers1
4CompletedTreatmentCoronary Heart Disease (CHD) / Gastrointestinal Bleeding1
4CompletedTreatmentHeartburn1

Pharmacoeconomics

Manufacturers
  • Lupin ltd
  • Navinta llc
  • Salix pharmaceuticals inc
  • Akorn strides llc
  • Apotex inc richmond hill
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Ben venue laboratories inc
  • Claris lifesciences ltd
  • Abbott laboratories
  • Baxter healthcare internati0nal specialty therapies div
  • Merck research laboratories div merck co inc
  • L perrigo co
  • Schwarz pharma inc
  • Actavis elizabeth llc
  • Alembic ltd
  • Apotex inc
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Perrigo co
  • Ranbaxy laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wockhardt ltd
  • Wockhardt americas inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Carlsbad Technology Inc.
  • Chain Drug
  • Corepharma LLC
  • CVS Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Johnson & Johnson Healthcare
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedium
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Salix Pharmaceuticals
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Strides Arcolab Limited
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Walgreen Co.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • Yung Shin Pharmaceutical Industry Ltd.
  • Zydus Pharmaceuticals
Dosage Forms
FormRouteStrength
Tablet, film coatedOral20 mg/1
Tablet, coatedOral
Tablet, film coatedOral20 MG
Tablet, film coatedOral40 MG
For suspensionOral40 mg/5mL
InjectionIntravenous10 mg/1mL
Injection, solutionIntravenous10 mg/1mL
Injection, solutionIntravenous2 mg/1mL
Powder, for solutionOral40 mg/5mL
Powder, for suspensionOral40 mg/5mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral40 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coated, extended releaseOral10 mg/1
SolutionIntravenous
Tablet, orally disintegratingOral20 mg/1
Tablet, orally disintegratingOral40 mg/1
Tablet, chewableOral
Injection, solutionIntravenous20 mg/50mL
Injection, solution, concentrateIntravenous10 mg/1mL
TabletOral10 mg
Tablet, chewableOral20 mg/1
TabletOral
Tablet, coatedOral10 mg/1
Prices
Unit descriptionCostUnit
Pepcid 30 40 mg tablet Bottle125.5USD bottle
Pepcid 40 mg/5ml Suspension 50ml Bottle123.88USD bottle
Pepcid 30 20 mg tablet Bottle64.13USD bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle10.15USD bottle
Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle9.23USD bottle
Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle7.99USD bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle7.99USD bottle
Famotidine 40 mg tablet3.43USD tablet
Pepcid 40 mg tablet3.02USD tablet
Famotidine powder2.74USD g
Famotidine 20 mg tablet1.76USD tablet
Pepcid 20 mg tablet1.6USD tablet
Apo-Famotidine 40 mg Tablet1.11USD tablet
Mylan-Famotidine 40 mg Tablet1.11USD tablet
Novo-Famotidine 40 mg Tablet1.11USD tablet
Nu-Famotidine 40 mg Tablet1.11USD tablet
Pepcid ac 10 mg tablet0.72USD tablet
Famotidine 40 mg/4 ml vial0.71USD ml
Famotidine 500 mg/50 ml vial0.71USD ml
Apo-Famotidine 20 mg Tablet0.62USD tablet
Mylan-Famotidine 20 mg Tablet0.62USD tablet
Novo-Famotidine 20 mg Tablet0.62USD tablet
Nu-Famotidine 20 mg Tablet0.62USD tablet
Pepcid ac 20 mg tablet0.58USD tablet
Famotidine-ns 20 mg/10 ml syrg0.54USD ml
Pepcid ac 10 mg gelcap0.48USD capsule
Pepcid complete tablet chew0.4USD tablet
Famotidine 20 mg/2 ml vial0.36USD ml
Famotidine 10 mg/ml vial0.28USD ml
CVS Pharmacy acid controller 20 mg tablet0.24USD tablet
CVS Pharmacy acid controller tablet0.24USD tablet
Acid reducer 20 mg tablet0.22USD tablet
Acid controller 10 mg tablet0.21USD tablet
Mylanta gas 125 mg tablet chew0.16USD tablet
Acid reducer 10 mg tablet0.15USD tablet
Famotidine 10 mg tablet0.15USD tablet
Famotidine 20 mg piggyback0.13USD ml
Mylanta gelcap0.12USD capsule
Mylanta ultimate-strength tablet0.07USD tablet
Mylanta ultra chew tablet0.06USD tablet
Pv acid reducer 10 mg tablet0.05USD tablet
Mylanta liq0.02USD ml
Mylanta supreme antacid liq0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5075114No1991-12-242010-05-23Us
CA2178277No2000-11-142016-06-05Canada
CA2052679No1997-12-022011-08-21Canada
US6221392No2001-04-242018-04-09Us
US6024981No2000-02-152018-04-09Us
US5854267Yes1998-12-292016-06-29Us
US6814978Yes2004-11-092022-02-26Us
US5989588Yes1999-11-232018-03-30Us
US8067451No2011-11-292026-07-18Us
US8501228No2013-08-062026-07-18Us
US8318202No2012-11-272026-07-18Us
US8449910No2013-05-282026-07-18Us
US8309127No2012-11-132026-07-18Us
US8067033No2011-11-292026-07-18Us
US5667794Yes1997-09-162015-11-02Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)163.5 °CPhysProp
water solubility1000 mg/L (at 20 °C)MERCK INDEX (1996)
logP-0.64ISLAM,MS & NARURKAR,MM (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.271 mg/mLALOGPS
logP-0.2ALOGPS
logP-2ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area175.83 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity80.46 m3·mol-1ChemAxon
Polarizability31.66 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5839
P-glycoprotein inhibitor INon-inhibitor0.9044
P-glycoprotein inhibitor IINon-inhibitor0.8701
Renal organic cation transporterNon-inhibitor0.6802
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9297
Ames testNon AMES toxic0.5827
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.9324
Rat acute toxicity1.9523 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Inhibitor0.6481
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-000i-0029000000-087ab7a1109f0568738d
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0udi-0900000000-d8a9ef8fc58c0c705232
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-000i-0900000000-e245f325e8c6f31a5fd0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0005-0940000000-a2bd7381011d29592cea
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0090000000-10306158f008021f19a5
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0090000000-90a70a7303c968311864
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-001i-0090000000-ac0250ad61059e58f431
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0090000000-235724a37e50732fdf94
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0950000000-0c16a77af1ba782fa15a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0950000000-02af106b93d1423b1342
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Targets

Details
1. Histamine H2 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Inan A, Sen M, Surgit O, Ergin M, Bozer M: Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo). 2009;64(6):567-70. [PubMed:19578661]
  3. Chremos AN: Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003. [PubMed:2887616]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP: Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54. doi: 10.1007/s00280-015-2727-6. Epub 2015 Apr 1. [PubMed:25829094]
  2. FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
  2. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
  3. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]
  4. FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM: The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet. 2016 Jun;55(6):711-21. doi: 10.1007/s40262-015-0346-3. [PubMed:26597253]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2020 22:18

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates